Cancer in Children, teenagers and young adults

Cancer in children, teenagers and young adults
National Cancer Registration and Analysis Service February 2021

• Data from the four UK national cancer registries to describe the incidence, survival and mortality from cancer diagnosed among children, teenagers and young adults resident in the United Kingdom. The analysis relates to children and young people who were diagnosed with cancer under the age of 25 during the 20-year period of 1997-2016. Includes survival charts 0-14yrs, 15-24 years and 0-24 years.

Cancer 62 Day Patient Target List to include waiting list breakdown

Cancer 62 Day Patient Target List (CANPTL62)
NHS Digital

• The 'Cancer 62 Day Patient Target List' (CANPTL62) collection is a weekly snapshot which shows the number of patients on the cancer 62-day pathway, who are at risk of breaching the 62-day standard (two month/62-day wait from urgent GP referral to first definitive treatment). From the 23 November 2020, this collection has been remodelled to also include waiting list breakdown by suspected tumour groups 62-day screening, consultant upgrades and further granularity about the start of treatment.

Cancer survival in England for patients diagnosed between 2014 and 2018, and followed up until 2019

Cancer survival in England for patients diagnosed between 2014 and 2018, and followed up until 2019
PHE 30 October 2020

• Cancer survival statistics for adults and children by stage at diagnosis and by different geographical variations.
• Main points
• Melanoma of the skin had the highest age-standardised net survival for 1-year in both males (97.6%) and females (98.8%) and for 5-year in males (90.1%) and females (94.5%) for diagnoses between 2014 and 2018.
• Pancreatic cancer had the lowest age-standardised net survival for 1-year in males (25.3%) and females (26.6%), and for 5-year in females (8.2%) for diagnoses between 2014 and 2018. For males, the lowest 5-year survival is in mesothelioma cancer (6.7%).
• We provide survival by stage estimates for 23 cancer sites. Stage data is complete for 86.8% of diagnoses in 2014 to 2018.
• Childhood cancer survival has continued to improve for 1-, 5- and 10-years, with the 5-year survival seeing the greatest improvement over time; an increase of 7.4 percentage points, from 77.2% in 2001 to 84.6% predicted for children diagnosed in 2019.
• For Cancer Alliances (CAs), the difference between the minimum and maximum 1-year survival estimates varies from 1.5 percentage points for breast cancer (females only) to 13.1 percentage points for brain cancer (all persons).
• All graphs can be found on the interactive R Shiny App.

NCARDRS congenital anomaly statistics: annual data

NCARDRS congenital anomaly statistics
PHE updated 12 August 2020

• The National Congenital Anomaly and Rare Disease Registration Service (NCARDRS) reports  give estimates of the national prevalence of congenital anomalies including structural, chromosomal and genetic anomalies.
• These reports present data collected since 2014.

Routes to Cancer Diagnosis data

Routes to Cancer Diagnosis 2010-2017
National Cancer Registration and Analysis Service (NCRAS) 14 July 2020

• Routes to Diagnosis categorises the pathways that lead to a patient’s diagnosis of cancer. These results provide an overview of the results for 2006 to 2017, showing the trends over time for all malignant neoplasms (excluding non-melanoma skin cancer) and a snapshot of results in 2017 for female breast, colorectal, lung and prostate cancers.
• One of the aspects highlighted by Routes to Diagnosis is the inequality in how people are diagnosed. A study by Herbert and others found that age and deprivation affect the route to diagnosis. Older people continue to make up the bulk of those diagnosed as an emergency presentation, and those who are more deprived are also more likely to be diagnosed through this route.

Oral cancer in England - Incidence, survival and mortality rates

Oral cancer in England
PHE 27 May 2020

• This report presents oral cancer data for England held by the National Cancer Registration and Analysis Service (NCRAS) and includes incidence, survival and mortality rates. It covers the period from 2012 to 2016, and the data is presented at national, regional, upper-tier and lower-tier local authority level.
• Stark inequalities in oral cancer exist between geographic areas and population groups, and there are opportunities to prevent oral cancer and to support early detection and treatment. The data in this report identifies the geographic areas and population groups most at risk to facilitate the planning of health improvement initiatives and clinical services.

Chemotherapy, Radiotherapy and Surgical Tumour Resections in England

Chemotherapy, Radiotherapy and Surgical Tumour Resections in England
PHE 8 April 2020

• Population-based statistics on cancers treated with chemotherapy, radiotherapy and surgical tumour resection which were diagnosed between 2013 and 2016 in England. 
• This commentary accompanies an interactive tool that breaks down treatment by age at diagnosis, stage at diagnosis, broad ethnic group, Charlson comorbidity index, income deprivation, sex, year of diagnosis and Cancer Alliance.

ICNARC Report on COVID-19 in critical care

Report on COVID-19 in critical care
Intensive Care National Audit and Research Centre (ICNARC) 04 April 2020

• A report on the first reported 2249 patients critically ill with COVID-19 across all NHS adult, general intensive care and combined intensive care/high dependency units in England, Wales and Northern Ireland, plus some specialist and non-NHS critical care units.
• Includes breakdown by demographics (incl ethnicity) shows a significantly higher % of non white patients than in general population.

Big data registries in spine surgery research: the lurking dangers

Big data registries in spine surgery research: the lurking dangers
BMJ Evidence-Based Medicine 22 March 2020. doi: 10.1136/bmjebm-2019-111333

• Spine surgery research has benefited from the use of national databases and registries. However inappropriate use of these registries continues to be a growing concern as potentially false or inaccurate conclusions can adversely impact clinical practice. Knowledge of methodological requirements in the use and analyses of registry data is essential to ensuring quality evidence with proper interpretation.

Multiple sclerosis: prevalence, incidence and smoking status - data briefing

Multiple sclerosis: prevalence, incidence and smoking status - data briefing
PHE 4 February 2020

• Findings from a study using a sample of anonymised primary care records in relation to the prevalence, incidence and demographic characteristics of patients with a diagnosis of multiple sclerosis (MS) in England.

Cancer services profiles: 2019 annual update

Cancer services profiles: 2019 annual update
PHE 3 December 2019

• Annual update of data in the cancer services profiles for the financial year 2018 to 2019.
• These profiles present data at GP, CCG and national level on:
• cancer incidence and screening
• Two Week Wait (TWW) referrals
• diagnostic services
• emergency presentations and admissions

The measurement maze

The measurement maze
Health Foundation November 2019

• This briefing takes a snapshot of national quality measures in three clinical areas with differing levels of national scrutiny – breast cancer, children and young people’s mental health (CYMPH), and renal care. 
• Supplementary reports include the identified  indicator lists (national-level quality indicators, local quality indicators and missing indicators) for each area.

National Clinical Improvement Programme Portal (GIRFT)

National Clinical Improvement Programme (NCIP)
Getting It Right First Time

• The National Clinical Improvement Programme (NCIP) portal is a digital tool that NHS consultants in England will use to review their personal patient outcomes data alongside comparable national and unit level data.
• Metrics are being developed for the following surgical specialties: cardiothoracic surgery, ENT, general surgery, neurosurgery, obstetrics and gynaecology, oral and maxillofacial surgery, ophthalmology, orthopaedics, paediatric surgery, spinal surgery, urology and vascular surgery.

The Get Data Out Programme

The Get Data Out Programme
National Cancer Registration and Analysis Service (NCRAS)

• The Get Data Out programme presents key statistics about cancer patients. 
• Patients diagnosed with a certain type of tumour are split into many smaller groups, each of which contains approximately 100 patients with the same characteristics. These are presented in an interactive dashboard. For each group of patients there are statistics about incidence, routes to diagnosis, treatments and survival.
• Prostate cancers were added to the programme in July 2019.

Measuring up: how does the UK compare internationally on cancer survival?

Measuring up: how does the UK compare internationally on cancer survival? [blog]
Cancer Research UK, 11 September 2019

• Latest data from International Cancer Benchmarking Partnership indicates that, except for  ovarian and oesophageal, the UK has the lowest survival figures for the cancers studied.
• Commentary on: 
• Progress in cancer survival, mortality, and incidence in seven high-income countries 1995–2014 (ICBP SURVMARK-2): a population-based study Lancet Oncology 11 September 2019 DOI: https://doi.org/10.1016/S1470-2045(19)30456-5

Cancer Outcome Metrics

Cancer Outcome Metrics
The National Cancer Registration and Analysis Service (NCRAS)

• Two cancer outcomes indicators refreshed on a quarterly basis:
• Official Statistics: Emergency Presentations (by CCG and Cancer Alliance, with commentary)
• Stage at Diagnosis

National Cancer Patient Experience Survey 2018 reports

National Cancer Patient Experience Survey 2018 reports
NCPES 4th September 2019

• Survey reports by CCG, Cancer Alliance, Trusts and national data.

CancerData dashboard

CancerData dashboard
NHS England and Public Health England

• The CancerData dashboard brings together data across the whole cancer pathway at CCG, provider and national levels.

Which cancers would benefit most from earlier diagnosis?

Which cancers would benefit most from earlier diagnosis?
ONS 18 June 2019

• While all cancers would benefit from earlier diagnosis, there are some cancers where earlier diagnosis would have a greater impact on survival. Colorectal and kidney cancer patients would see the greatest increase in their chances of survival if they were diagnosed at an earlier stage, data shows.
• The report includes proportion of people diagnosed at each stage, and overall net-survival for prostate, breast, kidney, colorectal, ovary and lung cancers.

Cancer Data and Statistics

Cancer Data and Statistics
CancerResearch UK

• National cancer statistics - Latest UK cancer statistics including key stats, in-depth explanations and raw data on cancer incidence, mortality, survival, risk, and diagnosis and treatment.
• Local cancer statistics - Local level cancer statistics; searchable by a local area or constituency in England.
• GP Practice data - Links to tools to inform local clinical practice around early detection and diagnosis of cancer.
• RoI tools - Tools for public health commissioners and decision-makers to model the effects of interventions, to estimate costs against the value of benefits and improvements.